RPL13AB Antibody

What is RPL13A and why is it important in research?

RPL13A (ribosomal protein L13a) is a structural component of the large 60S ribosomal subunit and a member of the L13 ribosomal protein family. Its significance extends beyond its canonical role in protein synthesis, as it serves as a stably expressed reference gene during differentiation and cellular expansion . More importantly, RPL13A functions as a key component of the IFN-gamma-activated inhibitor of translation (GAIT) complex, which regulates inflammation by inhibiting the translation of specific inflammation-related transcripts through binding to the 3' UTR of target mRNAs . This dual functionality in both ribosomal and extraribosomal processes makes RPL13A a significant target for research investigating cellular regulation, immune responses, and disease mechanisms.

How is RPL13A involved in immune responses and viral infections?

RPL13A plays a critical role in antiviral immune responses, particularly against viruses like foot-and-mouth disease virus (FMDV). Research has demonstrated that RPL13A overexpression promotes the induction and activation of nuclear factor-κB (NF-κB) and interferon-β (IFN-β) gene promoters, enhancing expression and secretion of antiviral factor IFN-β and proinflammatory cytokine interleukin-6 (IL-6) . This mechanism contributes to cellular defense against viral infection. In respiratory syncytial virus (RSV) infections, RPL13A can be released from the 60S ribosomal subunit and form a virus-activated translation inhibition complex (VAIT) when it recognizes specific hairpin structures in viral mRNA, thereby inhibiting viral protein translation . These extraribosomal functions highlight RPL13A's significance in host-pathogen interactions and innate immunity research.

What are the structural and biochemical properties of RPL13A that researchers should know?

Researchers working with RPL13A should be aware of its key biochemical properties for accurate experimental design and interpretation. Human RPL13A consists of 197 amino acids with a calculated molecular weight of approximately 23-24 kDa, though it is typically observed at 24-28 kDa on Western blots due to post-translational modifications . The complete amino acid sequence begins with MAEVQVLVLDGRGHLLGRLAAIVAKQVLLGRK and continues through a series of specific domains essential for its ribosomal and extraribosomal functions . RPL13A exhibits multiple cellular localizations including the cytoplasm, cytosol, cytosolic ribosome, focal adhesion sites, nucleolus, and nucleus . This distribution pattern reflects its diverse functions beyond protein synthesis and should be considered when designing subcellular localization experiments or interpreting immunostaining results.

What criteria should be considered when selecting an RPL13A antibody for specific applications?

When selecting an RPL13A antibody, researchers should evaluate several critical parameters based on their experimental requirements. First, confirm the antibody's validated applications—whether it's been tested for Western blot (WB), immunohistochemistry (IHC), immunofluorescence (ICC/IF), or ELISA . Next, review the species reactivity profile; many commercial RPL13A antibodies show cross-reactivity with human, mouse, and rat samples, which is advantageous for comparative studies . The antibody's clonality is another important consideration—polyclonal antibodies offer broader epitope recognition but potentially lower specificity compared to monoclonals. The immunogen used for antibody production should be examined; for instance, antibodies raised against recombinant fusion proteins containing amino acids 1-197 of human RPL13A may provide comprehensive protein recognition . Finally, review validation data such as positive control samples (e.g., A549, Jurkat, HEK-293, HeLa, RAW264.7 cells for Western blot applications) to ensure the antibody performs reliably in your experimental system.

How can researchers validate RPL13A antibody specificity for their experimental systems?

Validating RPL13A antibody specificity requires a multi-pronged approach to ensure reliable results. Begin with a Western blot analysis using positive control samples such as HeLa, HCT116, or COS-7 cells, which are known to express detectable levels of RPL13A . Look for a clean band at the expected molecular weight (23-28 kDa) . Next, conduct a knockdown/knockout validation experiment where RPL13A expression is reduced through siRNA or CRISPR-Cas9, which should result in corresponding reduction or elimination of the specific band. Peptide competition assays, where the antibody is pre-incubated with excess immunizing peptide before application, can confirm binding specificity—the target band should disappear or be significantly reduced. For immunostaining applications, test specificity by comparing staining patterns with the established subcellular localization profile of RPL13A (cytoplasm, nucleolus, and ribosomal locations) . Finally, parallel validation using two different antibodies targeting distinct RPL13A epitopes can provide additional confidence in specificity. This comprehensive validation strategy ensures that experimental observations reflect authentic RPL13A biology rather than antibody artifacts.

What are the optimal conditions for using RPL13A antibodies in Western blot experiments?

Achieving optimal Western blot results with RPL13A antibodies requires careful attention to several methodological parameters. For protein extraction, use RIPA buffer containing protease inhibitors to preserve RPL13A integrity, particularly when investigating its extraribosomal functions in immune responses . Load 20-30 μg of total protein per lane and separate on a 12-15% SDS-PAGE gel to effectively resolve the 23-28 kDa RPL13A protein . After transfer to a PVDF or nitrocellulose membrane, block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature. Apply the primary RPL13A antibody at the manufacturer's recommended dilution—typically 1:1000-1:5000 for Western blot applications —and incubate overnight at 4°C for optimal antigen-antibody binding. After thorough washing, apply an appropriate HRP-conjugated secondary antibody (typically at 1:5000-1:10000) for 1 hour at room temperature. When imaging, be prepared to observe RPL13A at an apparent molecular weight of 24-28 kDa, which may differ slightly from the calculated weight of 23-24 kDa due to post-translational modifications . Positive controls should include lysates from cell lines known to express RPL13A, such as HeLa, A549, or HEK-293 cells .

How should researchers optimize immunohistochemistry protocols for RPL13A detection in tissue samples?

Optimizing immunohistochemistry (IHC) protocols for RPL13A detection requires careful attention to tissue processing and antigen retrieval methods. Begin with proper fixation using 10% neutral buffered formalin for 24-48 hours, followed by paraffin embedding and sectioning at 4-6 μm thickness. The critical step for successful RPL13A detection is antigen retrieval—search results recommend using TE buffer at pH 9.0, although citrate buffer at pH 6.0 may serve as an alternative . Heat-induced epitope retrieval using a pressure cooker or microwave is generally more effective than enzymatic methods for exposing RPL13A epitopes. For the immunostaining procedure, block endogenous peroxidase activity with 3% hydrogen peroxide, then block non-specific binding with 5% normal serum from the species of the secondary antibody. Apply the RPL13A primary antibody at a dilution of 1:200-1:800 and incubate overnight at 4°C in a humidified chamber. Use an appropriate detection system (e.g., polymer-based or avidin-biotin complex) with DAB as the chromogen. Human stomach cancer tissue has been validated as a positive control for RPL13A detection . For multiplex staining to investigate RPL13A's relationship with inflammation markers, carefully optimize antibody dilutions and detection systems to prevent cross-reactivity while enabling colocalization analysis.

What methodological approaches can be used to study RPL13A's role in protein-protein interactions and complex formation?

Investigating RPL13A's protein-protein interactions and complex formation—particularly its role in the GAIT complex and antiviral responses—requires specialized methodological approaches. Co-immunoprecipitation (Co-IP) represents a primary technique for studying these interactions: cell lysates can be prepared using RIPA buffer containing protease and RNase inhibitors, pretreated with Protein A beads to remove non-specific binding proteins, then incubated with anti-RPL13A antibody overnight at 4°C before adding fresh Protein A beads for precipitation . This approach has successfully demonstrated interactions between RPL13A and viral components like the FMDV 3C protease . For confirming direct interactions, proximity ligation assays (PLA) offer in situ detection with high sensitivity and specificity. To study dynamic complex formation, fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) using fluorescently tagged RPL13A constructs enables live-cell visualization of interaction kinetics. For broader interactome analysis, RPL13A antibody-based immunoprecipitation followed by mass spectrometry can identify novel binding partners. When studying the GAIT complex specifically, RNA immunoprecipitation (RIP) assays using RPL13A antibodies can help identify target mRNAs regulated by this complex. These complementary approaches provide a comprehensive toolkit for dissecting RPL13A's diverse extraribosomal functions in immune regulation and antiviral responses.

How does RPL13A contribute to antiviral immune responses beyond its ribosomal functions?

RPL13A's extraribosomal functions in antiviral immunity represent a sophisticated example of biological multitasking that researchers are increasingly investigating. Studies have demonstrated that RPL13A overexpression significantly enhances the innate immune response by promoting activation of NF-κB and IFN-β promoters, leading to increased expression and secretion of antiviral factor IFN-β and proinflammatory cytokine IL-6 . This immunomodulatory capacity operates through distinct mechanisms depending on the viral infection context. During foot-and-mouth disease virus (FMDV) infection, RPL13A functions as a positive regulator of antiviral immunity, with its knockdown resulting in enhanced viral replication . Intriguingly, some viruses have evolved countermeasures—FMDV 3C protease directly interacts with RPL13A and reduces its expression, effectively antagonizing the RPL13A-mediated antiviral response . In respiratory syncytial virus (RSV) infections, RPL13A forms part of the virus-activated translation inhibition complex (VAIT), recognizing specific structures in viral mRNAs to suppress their translation . This dynamic interplay between RPL13A and viral factors represents an important research frontier for understanding host-pathogen interactions and developing novel antiviral strategies that might enhance RPL13A-mediated immune responses.

What experimental approaches can resolve contradictory findings about RPL13A function in different cellular contexts?

Resolving contradictory findings about RPL13A function across different cellular contexts requires sophisticated experimental designs that account for cell-type specificity, activation states, and temporal dynamics. Start with systematic cross-platform validation using multiple detection methods—qPCR for transcript levels, Western blot for protein expression, and immunofluorescence for localization—across standardized cell models. Implement tissue-specific or inducible knockout/knockdown systems using CRISPR-Cas9 or shRNA approaches to evaluate context-dependent phenotypes. Temporal analysis is crucial: use time-course experiments with synchronized cell populations to capture dynamic changes in RPL13A localization and function, particularly during immune activation or viral infection . For mechanistic understanding, conduct parallel interactome analysis via immunoprecipitation-mass spectrometry across different cell types or activation states to identify context-specific binding partners that might explain functional divergence. Phosphoproteomics can reveal post-translational modifications of RPL13A that potentially regulate its function—particularly important as RPL13A is known to be phosphorylated when incorporated into the GAIT complex . Finally, conduct rescue experiments where contradictory phenotypes are observed, reintroducing wild-type or mutant RPL13A to determine which domains are responsible for context-specific functions. This multifaceted approach can reconcile apparently contradictory findings by revealing how cellular context influences RPL13A's diverse ribosomal and extraribosomal functions.

How can researchers distinguish between RPL13A's ribosomal and extraribosomal functions in experimental systems?

Distinguishing between RPL13A's ribosomal and extraribosomal functions requires sophisticated experimental designs that selectively target these distinct activities. Domain-specific mutagenesis represents a powerful approach: identify and mutate specific residues or domains required for RPL13A's incorporation into ribosomes versus its participation in the GAIT complex or antiviral responses, then express these mutants in RPL13A-depleted cells to selectively rescue specific functions. Subcellular fractionation with differential centrifugation can physically separate ribosome-associated RPL13A from cytosolic pools involved in extraribosomal activities, allowing separate biochemical analysis of each fraction. For studying dynamic transitions between these functions, real-time imaging using fluorescently tagged RPL13A combined with ribosomal markers can visualize how stimuli like IFN-γ treatment trigger RPL13A release from ribosomes to form the GAIT complex . Selective inhibition approaches are also valuable—use targeted degradation methods like dTAG or specific inhibitors of ribosomal biogenesis to disrupt ribosomal functions while potentially preserving extraribosomal activities. RNA-protein interaction studies can specifically investigate RPL13A binding to inflammatory mRNAs in the GAIT complex versus its interactions with ribosomal RNA. By systematically implementing these approaches, researchers can parse the distinct contributions of RPL13A to protein synthesis versus its specialized roles in immune regulation and antiviral defense.

What are common challenges when using RPL13A antibodies and how can researchers address them?

Researchers using RPL13A antibodies commonly encounter several technical challenges that require systematic troubleshooting. One frequent issue is background staining in immunohistochemistry or immunofluorescence, which can be addressed by optimizing antibody dilution (typically starting with 1:200-1:800 for IHC applications ), extending blocking steps to 2 hours with 5% BSA or normal serum, and implementing more stringent washing protocols. For Western blot applications, multiple bands near the expected 24-28 kDa size may appear due to post-translational modifications or degradation products . This can be resolved by using fresher samples, adding additional protease inhibitors during extraction, and optimizing sample heating conditions. Inconsistent detection sensitivity between experiments often stems from variable epitope accessibility; standardizing antigen retrieval methods (preferably using TE buffer at pH 9.0 as recommended ) can improve reproducibility. When studying RPL13A in infection models, decreased antibody reactivity might result from viral protease-mediated degradation, as seen with FMDV 3C protease —using protease inhibitors or shorter infection timepoints can help maintain detection. For co-immunoprecipitation experiments investigating RPL13A interactions, weak or false negative results might occur; adding RNase inhibitors to preservation buffers is crucial since many RPL13A interactions are RNA-dependent . By systematically addressing these common challenges, researchers can achieve more consistent and reliable results when studying this multifunctional ribosomal protein.

What are the best practices for quantifying RPL13A expression levels in different experimental systems?

Accurate quantification of RPL13A expression across experimental systems requires rigorous standardization and multi-method validation. For Western blot quantification, implement a standard curve using purified recombinant RPL13A protein alongside your samples to establish linearity of detection. Always normalize RPL13A signals to multiple housekeeping controls appropriate for your experimental conditions—actin or GAPDH for general normalization, and alternative ribosomal proteins like RPL7 for studying specific RPL13A depletion. For transcript analysis, qRT-PCR should employ validated primers with documented efficiency curves, and results should be normalized to multiple reference genes whose stability has been verified under your experimental conditions. When performing immunofluorescence quantification, use automated image analysis with consistent acquisition parameters and standardized intensity thresholds across experiments, complemented by Z-stack imaging to capture the full three-dimensional distribution of RPL13A across cellular compartments. For higher precision in detecting subtle changes, consider flow cytometry with RPL13A antibodies optimized for intracellular staining, which provides population-level quantification with single-cell resolution. In disease models or clinical samples, where RPL13A may serve as a biomarker, multiplex immunoassays allow simultaneous quantification of RPL13A alongside relevant cytokines or signaling molecules. This comprehensive approach ensures reliable cross-system comparison of RPL13A expression levels.

How can researchers effectively study post-translational modifications of RPL13A and their functional significance?

Studying post-translational modifications (PTMs) of RPL13A requires specialized techniques to detect these modifications and determine their functional consequences. Begin with phospho-specific antibodies or Phos-tag SDS-PAGE to identify phosphorylation states of RPL13A—particularly important since phosphorylation regulates its incorporation into the GAIT complex . For comprehensive PTM profiling, implement immunoprecipitation of RPL13A from differentially stimulated cells (e.g., with IFN-γ or during viral infection) followed by mass spectrometry analysis optimized for PTM detection. To establish functional significance, create phosphomimetic (e.g., S/T to D/E) and phospho-dead (S/T to A) mutations at key residues and express these in RPL13A-depleted cells to assess their impact on ribosome incorporation, GAIT complex formation, and antiviral responses. For temporal dynamics of modifications, use pulse-chase labeling with metabolic precursors specific to certain modifications. To study ubiquitination or SUMOylation, employ tandem ubiquitin binding entities (TUBEs) or SUMO-traps during immunoprecipitation to enrich modified forms. In situ proximity ligation assays using antibodies against RPL13A and specific modifications can visualize modified subpopulations within distinct cellular compartments. These approaches collectively provide a powerful toolkit for deciphering how post-translational modifications regulate RPL13A's transition between ribosomal functions and specialized extraribosomal roles in immune regulation and antiviral defense.

How can RPL13A antibodies be utilized in investigating disease mechanisms and biomarker development?

RPL13A antibodies offer powerful tools for investigating disease mechanisms across multiple pathological conditions. In cancer research, multiplex immunohistochemistry combining RPL13A antibodies with proliferation markers can reveal correlations between ribosomal biogenesis alterations and tumor progression, as RPL13A dysregulation has been linked to various malignancies . For inflammatory disorders, co-immunoprecipitation with RPL13A antibodies followed by RNA sequencing can identify disease-specific mRNA targets regulated by the GAIT complex, potentially revealing novel therapeutic targets. In viral pathogenesis studies, using RPL13A antibodies in combination with viral protein staining can map the spatiotemporal dynamics of host-defense mechanisms, particularly relevant given RPL13A's demonstrated role in inhibiting foot-and-mouth disease virus replication . For potential biomarker development, quantitative immunoassays using RPL13A antibodies can assess whether altered RPL13A expression or localization correlates with disease progression or treatment response. In neurodegenerative disorders, where ribosomal stress is increasingly recognized as a pathogenic factor, RPL13A immunostaining in brain tissues may reveal altered distribution patterns associated with disease. Through these diverse applications, RPL13A antibodies serve not only as research tools but also as potential contributors to diagnostic and prognostic methodologies across multiple disease contexts.

What methodological considerations are important when using RPL13A as a reference gene in gene expression studies?

While RPL13A is frequently used as a reference gene due to its relatively stable expression across many experimental conditions, researchers must implement several methodological checks before relying on it for normalization. First, conduct preliminary validation experiments to confirm RPL13A expression stability specifically in your experimental system, tissue type, and treatment conditions, as its suitability varies across contexts despite being generally stable during differentiation and cell expansion . Employ algorithms like geNorm, NormFinder, or BestKeeper to quantitatively assess RPL13A stability relative to other potential reference genes in your specific experimental conditions. Never rely solely on RPL13A—instead, use a minimum of three validated reference genes for normalization to improve reliability. Be particularly cautious when studying inflammatory conditions or viral infections, as these can alter RPL13A's extraribosomal functions and potentially its expression levels . When designing qPCR assays, place primers in constitutively expressed exons to avoid amplification of potential splice variants. Importantly, RPL13A should be avoided as a reference gene in studies specifically investigating ribosomal biogenesis, translation regulation, or the GAIT complex, as these directly involve RPL13A functionality. Regular verification of reference gene stability throughout long-term studies is essential, as conditions like cellular differentiation may eventually impact expression consistency. These precautions ensure that RPL13A serves as a reliable normalization control when appropriate, while avoiding potential circular reasoning in experimental designs where RPL13A itself might be regulated.